20
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T11703 | JAK-IN-1 | Others | |
JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively. | |||
T38436 | JAK-2/3-IN-1 | ||
JAK-2/3-IN-1 is a highly effective inhibitor targeting both JAK-2 and JAK-3 isoforms. It exhibits remarkable potency, with Ki values below 250 nM for both isoforms. | |||
T35899 | JAK1-IN-8 | JAK1-IN-8 | JAK |
JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM). | |||
T11706 | Londamocitinib | AZD4604 | JAK |
Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity. | |||
T78607 | JAK-STAT-IN-1 | JAK , STAT | |
JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases. | |||
T63086 | SYK/JAK-IN-1 | ||
SYK/JAK-IN-1 is a dual SYK/JAK inhibitor with IC50 values of less than 5 nM for both SYK and JAK2. | |||
T79807 | JAK kinase-IN-1 | JAK | |
JAK kinase-IN-1 (Example 1) functions as a potent inhibitor targeting the JAK family, which includes TYK2, JAK1, JAK2, and JAK3, with IC50 values of 4.2 nM, 32 nM, 27 nM, and 3473 nM, respectively [1]. | |||
T15607 | JAK3-IN-1 | Others | |
JAK3-IN-1 is a selective and orally active JAK3 inhibitor (IC50: 4.8 nM). JAK3-IN-1 displays over 180-fold more selective for JAK3 than JAK1 (IC50: 896 nM) and JAK2 (IC50: 1050 nM). | |||
T79768 | HDAC/JAK/BRD4-IN-1 | Epigenetic Reader Domain | |
HDAC/JAK/BRD4-IN-1 (compound 25ap) is a potent triple inhibitor targeting HDAC, JAK, and BRD4. This compound not only inhibits cell proliferation but also induces apoptosis in MDA-MB-231 cells and demonstrates in vivo an... | |||
T9814 | JAK3/BTK-IN-1 | JAK , BTK | |
JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two important targets in autoimmune diseases. JAK3/ BTk-in-1 simultaneously inh... | |||
T11707 | JAK2/FLT3-IN-1 | JNK | |
JAK2/FLT3-IN-1 has anti-cancer activity. JAK2/FLT3-IN-1 is a potent and orally effective dual JAK2/FLT3 (Janus kinase 2/ FMS-like tyrosine kinase 3) inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, F... | |||
T15606 | JAK1-IN-4 | JAK | |
JAK1-IN-4 is a selective JAK1 inhibitor (IC50s: 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively). JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC50, 227 nM). | |||
T39314 | JAK1/TYK2-IN-1 | JAK1/TYK2-IN-1 | |
JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively). | |||
T35898 | Izencitinib | ||
Izencitinib (TD-1473) is an orally active, gut-restricted JAK inhibitor with non-selective properties. It is primarily employed in the investigation of ulcerative colitis [1]. | |||
T7503 | Upadacitinib | ABT-494 | JAK |
Upadacitinib (ABT-494) (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM. | |||
T1849 | Momelotinib | CYT11387,CYT387,LM-1149 | Apoptosis , JAK , Autophagy |
Momelotinib (LM-1149) is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with IC50 of 11 nM/18 nM. JAK1/2 inhibitor CYT387 competes with JAK1/2 for ATP binding, which may result in inhib... | |||
TN1567 | Delphinidin chloride | Estrogen Receptor/ERR , VEGFR | |
Delphinidin chloride, a natural plant pigment found in berries and red wine, is a precursor of certain anthocyanins. Delphinidin chloride induces the release of nitric oxide from the vascular endothelium, resulting in va... | |||
T5S1897 | Linderalactone | Apoptosis , Others , JAK | |
1. Linderalactone showed significant inhibitory effects on superoxide anion generation by human neutrophils in response to fMLP/CB, values of IC5 is 8.48 μg/mL. | |||
T3673 | Mollugin | Rubimaillin | HER , JAK |
Mollugin (Rubimaillin) may be a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway. Mollugin as a candidate for a chemotherapeutic agent in OSCCs via the upr... | |||
T6S1141 | Ganoderic acid A | Apoptosis , NF-κB , Endogenous Metabolite , Autophagy | |
1. Ganoderic acid A exhibits antitumor activity, mediated through its inhibitory effect on nuclear transcription factor-kappaB and activator protein-1. 2. Ganoderic acid A can induce proliferation inhibition, apoptosis a... |